OPEN Regional Meeting June 26 and June 27, 2015 Hyatt Regency Pier Sixty Six 2301 Southeast 17th Street Fort Lauderdale, Florida, AGENDA

Transcription

1 OPEN Regional Meeting June 26 and June 27, 2015 Hyatt Regency Pier Sixty Six 2301 Southeast 17th Street Fort Lauderdale, Florida, Friday, June 26 AGENDA 10:00 am - 10:45 am Registration; Breakfast in the Exhibitor Pavilion 10:45 am - 11:00 am Introduction and Welcome 11:00 am - 12:00 pm Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents Patrick J. Medina, PharmD, BCOP University of Oklahoma College of Pharmacy Review the impact the pathophysiology of RCC has on the choice of drug therapy in both the adjuvant and metastatic treatment of renal cell cancers. A review of trial design and preliminary data (if available) of targeted agents used in the adjuvant setting will be presented. Data reviewing both FDA approved indications, and comparisons between targeted agents, used for metastatic RCC will also be presented. Finally, drug monitoring parameters and potential markers of response will be evaluated. Application Based. Activity Number: L01-P. CE Hours: :00 pm - 1:00 pm Lunch in the Exhibitor Pavilion Outline the pathophysiology of RCC and how this impacts drug selection. Review the use of targeted agents in the adjuvant treatment of RCC. Analyze the trial data to make appropriate first-line treatment recommendations for metastatic RCC. Given patient specific information select appropriate medications to treat metastatic RCC; including the appropriate sequencing of agent for patients who have progressed on initial therapy. Describe the mechanism of action, adverse reactions, and monitoring parameters of targeted agents used to treat RCC. 1:00 pm - 2:00 pm Novel Therapeutic Options for Non-Hodgkin Lymphoma Christopher A. Fausel, PharmD, MHA, BCOP Indiana University Simon Cancer Center Identify a number of advances in treating various histopathologic subtypes on non-hodgkin lymphoma. Emphasis will be placed on the incorporation of targeted

2 therapy agents either alone or in combination with standard cytotoxic agents. Primary literature will be reviewed for first-line and salvage therapy for the most common histopathologic subtypes of non-hodgkin lymphoma and appropriate supportive care measure for these treatments will be highlighted. Application Based. Activity Number: L01-P. CE Hours: 1.0 Review historical treatment regimens for non-hodgkin lymphoma and the evidence supporting their use. Delineate emerging therapies into the treatment paradigm of non-hodgkin lymphoma across multiple histopathologic subtypes. Describe how pharmacists can ensure appropriate supportive care for patients during treatment for non-hodgkin lymphoma. 2:00 pm - 2:15 pm Refreshments in the Exhibitor Pavilion 2:15 pm - 3:15 pm Case Studies in Multiple Myeloma: Integrating Novel Agents into Practice R. Donald Harvey, PharmD, FCCP, BCOP Winship Cancer Institute of Emory University Gain knowledge on treatment advances in multiple myeloma. Participants will evaluate the safety and efficacy results from recent clinical trials of emerging treatments. There will be an opportunity to apply the trial data to patient cases to optimize evidence based treatment. Application Based. Activity Number: L01-P. CE Hours: 1.0 Review the clinical manifestations and treatment advances in multiple myeloma. Evaluate recently published clinical trial data on safety and efficacy of novel treatments in multiple myeloma. Apply clinical trial information to specific patient cases for optimal evidencebased treatment. 3:15 pm - 3:45 pm Refreshments in the Exhibitor Pavilion 3:45 pm - 4:45 pm Practical Issues with New Targeted Therapies for Cancer Sarah L. Scarpace, PharmD, MPH, BCOP Associate Professor, Albany College of Pharmacy Review issues in the changing landscape for dispensing new agents and discuss categories/ causes which can affect adherence such as (rems, specialty pharmacy distribution, handling & storage, unique administration requirements) and awareness of new or unrecognized drug interactions which can which will negatively impact patient outcomes. Pharmacists will learn how they can help to mitigate these potential barriers in order to optimize therapy. Application Based. Activity Number: L01-P. CE Hours: 1.0 4:45 pm - 5:00 pm Break Describe evidence-based consequences of non-adherence. Evaluate theoretical drug interactions for clinical significance. Recognize areas which can affect therapeutic outcomes such as handling & storage, specialty pharmacy distribution, and unique administration requirements. 5:00 pm - 6:00 pm Biosimilars: Is This Really a Generic Vs Innovator Debate? (LAW) Jim Koeller, MS University of Texas at Austin

3 Review the nuances of biosimilar regulation and development so that pharmacy practitioners can make informed decisions about how to incorporate biosimilars into the medication use process at their respective institutions. Application Based. Activity Number: L03-P. CE Hours: 1.0 Define biosimilars and explain recent federal regulations. Differentiate between biosimilars and interchangeable products. Describe what the pharmacist role should be in handling biosimilar and interchangeable products. Saturday, June 27 7:00 am - 7:30 am Registration; Breakfast in the Exhibitor Pavilion 7:30 am - 8:30 am New Trends in the Management of Metastatic Breast Cancer Chad Barnett, PharmD, BCOP The University of Texas MD Anderson Cancer Center Hear the most recent developments in treatments for metastatic breast cancer, including new and emerging drugs. The presentation will address efficacy data supporting use of the drugs as well as potential toxicities. Application Based. Activity Number: L01-P. 1.0 Credit Hours: 1.0 Evaluate the efficacy and toxicity of new pharmacological therapies for management of patients with metastatic breast cancer. Analyze current data for new & emerging treatments of patients with metastatic breast cancer. Discuss the management of adverse events associated with therapeutic agents for patients with metastatic breast cancer. 8:40 am - 9:40 am GI Malignancies: An Update on Current Treatments Trevor McKibbin, PharmD, MS, BCOP Winship Cancer Institute of Emory University Identify the current treatments and controversies regarding the treatment of gastrointestinal malignancies, focusing on gastric and colon cancer. Application Based. Activity Number: L01-P. 1.0 Credit Hours: 1.0 Outline traditional and novel therapies in the treatment of colon and gastric cancers including the benefits and limitations of each regimen. Develop a treatment plan for a patient with either colon cancer or gastric cancer, using a given set of biomarkers. Discuss emerging therapies for the treatment of gastric and colorectal cancers. 9:50 am - 10:50 am Integrating Palliative Care in the Outpatient Setting Suzanne Amato Nesbit, PharmD, BCPS, CPE The Johns Hopkins Hospital Gain insight on the importance of palliative care in improving the quality of life of patients with cancer. Examine common barriers to implementing effective palliative care practices with a focus on the emerging role of the pharmacist to improve outcomes. Application Based. Activity Number: L01- P. Credit Hours: 1.0 Summarize the evidence supporting the significant impact of palliative care on relevant outcomes.

4 Describe the barriers to implementing palliative care practices in outpatient and private practice hematology/oncology settings. Explain the emerging role of the pharmacist in promoting and optimizing palliative services within the Vision for Comprehensive Cancer Care in :00 am - 12:00 pm Chronic Lymphocytic Leukemia (CLL): A Review of New and Emerging Treatment Options R. Donald Harvey, PharmD, FCCP, BCOP Winship Cancer Institute of Emory University There have been remarkable advances in our understanding of the biology and therapeutics of chronic lymphocytic leukemia (CLL). Pharmacists need to understand the current treatment recommendations and emerging therapeutics. This program will help pharmacists make sense of the array of CLL treatment options currently available and emerging. Application Based. Activity Number: L01-P. Credit Hours: 1.0 Summarize current treatment options for the treatment of CLL, including treatment outcomes and side effect profiles. Interpret new data on novel agents and therapeutic approaches with potential importance in the treatment of patients with chronic lymphocytic leukemia. Review emerging treatment options for CLL. 12:00 pm - 1:00 pm Buffet Lunch in the Exhibitor Pavilion 1:00 pm - 2:00 pm Pharmacotherapy of Malignant Melanoma Lew Iacovelli, BS, PharmD, BCOP, CPP Cone Health Cancer Center Several new agents have been approved by the FDA for the treatment of melanoma, and recent clinical data indicate that additional agents are on the horizon. This program will help pharmacists understand these new and emerging therapies and how to optimally prevent and manage toxicities. Application Based. Activity Number: L01-P. Credit Hours: 1.0 Discuss the indications and use of recently approved agents used in the treatment of melanoma. Illustrate methods for monitoring and managing toxicity in patients receiving recently approved agents used in the treatment of melanoma. Appraise ongoing clinic trial data with these newer agents with respect to their place as therapy options for patients with melanoma. 2:10 pm - 3:10 pm Update on Advanced Non-Small Cell Lung Cancer: Focus on Targeted Therapies Val R. Adams, PharmD, BCOP, FCCP University of Kentucky College of Pharmacy The treatment guidelines for NSCLC have been revised to optimize outcomes; therapy recommendations are now directed by stage, histology, and genetic mutational drivers. Pharmacists need to know how to incorporate changes to therapy guidelines into practice. However, because many of the latest advances in NSCLC care make use of targeted therapies, from which not all patients would benefit, pharmacists also need to know which patients should receive which therapy. This program will help pharmacists understand the role of targeted therapies in the management of NSCLC. Application Based. Activity Number: L01-P. Credit Hours: 1.0

5 Recognize the therapeutic role for EGFR inhibitors, VEGF inhibitors, and PD1 inhibitors for advanced non-small cell lung cancer. Recommend appropriate toxicity prevention, monitoring, and treatment for select novel agents in each therapeutic class. Identify targetable pathways where drug therapy is currently being investigated. 3:20 pm - 4:20 pm Improving Compounding Practices while Protecting Healthcare Workers Handling Hazardous Drugs (LAW) Eric Kastango, MBA, RPh, FASHP Clinical IQ, LLC The national outbreak of the fungal meningitis from contaminated medication has been a call to action to comply with the federally enforceable USP chapters on compounding and their state pharmacy laws and regulations. Recently, USP published a new chapter on the safe handling of hazardous drugs. Washington State, California and Maryland have passed legislation designed to protect healthcare workers handling hazardous drugs. This presentation will explore what pharmacists will need to know to understand and comply with applicable rules and regulations as it relates to compounding and occupational exposure to hazardous drugs. Knowledge Based. Activity Number: L03-P. Credit Hours: 1.0 *Agenda Subject to Change Describe the current regulatory environment for pharmacies that compound sterile medications. Discuss the major proposed requirements of the new USP hazardous drug chapter. Describe the various state and national initiatives designed to protect healthcare workers handling hazardous drugs. Describe risk mitigation strategy to provide safe compounded medication while protecting healthcare workers handling hazardous drugs. Continuing Education This programming has been designed to meet the educational needs of pharmacists, nurses and other interested healthcare professionals specializing in hematology/oncology practice. Earn up to 12 Contact Hours (1.2 CEUs) - Includes 2 hours of Law Credits Sessions are individually accredited Conference : Participants will be able to demonstrate clinical knowledge and ability to counsel patients in the areas of: RCC, Non-Hodgkin Lymphoma, GI Malignancies, Breast Cancer, Compounding, Adherence, Multiple Myeloma, Palliative Care, Chronic Lymphocytic Leukemia, Melanoma, NSCLC, and Biosimilars. Pharmacists: American Health Resources, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Nurses: American Health Resources, Inc. is approved by the California Board of Registered Nursing, Provider # CEP and approved this program for 1.0 contact hour for each 1 hour session completed. Please check with licensing board to verify credits can be claimed in your state. Requirements for CE Credit To receive credit participants must fully attend each session (no partial credit will be given) as well as pass in a completed signature verification sheet; for pharmacists please include your NAPB e-profile number. Statements of Credit will be issued to participants by logging onto and completing the session evaluation

6 form for each session attended. Your continuing pharmacy education credit is automatically reported to CPE Monitor. All participants will have the opportunity to evaluate the educational sessions and presenters as well as the ability to identify their future educational needs. Participants can earn Continuing Pharmacy Education credits for this program by going to and completing the session evaluation form for session(s) attended within 60 days of session date. After completion of the activity evaluation, your continuing pharmacy education credit is automatically reported to CPE Monitor where a certificate of credit can be printed. Please allow up to 48 hours for credit to be available on the CPE Monitor. Participant names will be checked against program attendance sheets for verification of attendance. Only Certificates of Credit issued from CPE Monitor are valid in the U.S. CPE Monitor will not accept credits after 60 days from session date. This meeting is registered with FL CE Broker: Provider # , Course # Registration and Pricing ACCC Members: $95 (1 day) or $120 (2 days) ~ Discounted rates are $72/ $90 Non-ACCC members: $120 (1 day) or $150 (2 days) ~ Discounted rates are $90/$113 Take advantage of a 25% early bird rate until June 15! Enter code FL25 at checkout. Register at Hotel Information For reservations at Hyatt Regency Pier Sixty Six, please call and mention the Oncology Pharmacy Education Network Meeting to receive the discounted rate of $119.00/night (plus tax). The group rate will be available until May 25, 2015, and is subject to availability. Outdoor valet parking is $30/day, outdoor self parking is $25/day, and visitor valet parking is $11/day (plus 6% sales tax/day). Questions? Contact American Health Resources via at eventsinfo@ahrevents.com or call This OPEN meeting is supported by educational grants from: Amgen Inc. AstraZeneca Boehringer Ingelheim Pharmaceuticals, Inc. Bristol-Myers Squibb Celgene Company Hospira, Inc. Lilly Merck Sharp & Dohme Corp. Novartis Onyx Pharmaceuticals, an Amgen subsidiary Takeda Oncology This Oncology Pharmacy Education Network meeting is brought to you by: